Triomics

Congratulations to @Triomicsinc on their $22M Series B. But the real story isn't the round. It's what they're solving. @k__sarim | @hrituraj1997 | @b_jishnu

Excited for @BatteryVentures to lead the $22M round for @Triomicsinc and to join the board. Oncology is one of the hardest areas to deploy AI due to the complexity of patient records (can be 300+ pages and 80%+ unstructured).

A complex cancer patient's record can run 300+ pages, and roughly 80% of it is unstructured: clinical notes, radiology, scanned PDFs, faxes from outside providers. Reading and reasoning over those records has required human judgment at every step, creating a bottleneck in nearly every workflow in cancer care. @Triomicsinc has built the oncology-specific AI infrastructure to change that. We’re excited to lead the company’s $22M round, with @BrandonGleklen joining the Board of Directors. Founders Sarim Khan (@k__sarim) and Raj Singh (@hrituraj1997) built Triomics with a clear philosophy: you need to deeply understand both oncology and AI workflows to know what “correct” means in the context of hundreds of pages of unstructured data. Their OncoLLM architecture reads the full patient record and produces a structured longitudinal profile that incorporates every clinical note, lab result and imaging readout. Sitting on top of that foundation is a growing set of products that help oncology teams prepare for patient visits, identify eligible clinical trial candidates, populate disease registries and curate real-world data for research. Leading cancer centers and some of the nation's largest community oncology practices already trust Triomics to power their clinical and research workflows.  Congratulations to Sarim, Raj and the Triomics team. More on why we invested at okt.to/jpHQ2R

We're excited to double down on @Triomicsinc's Series B as they continue to expand their oncology-specific AI platform for cancer centers. Oncology breakthroughs are keeping patients alive longer, but patient histories are growing into dense, multi-year records that take clinicians a long time to navigate. Triomics helps oncologists and administrative staff cut through that complexity. Starting with clinical trial matching, the platform has since expanded to include verifiable patient summaries that surface key information directly inside the tools clinicians already use, reducing appointment prep time without adding new workflows. Congratulations to @k__sarim, @hrituraj1997, and the team! More about the fundraise: techcrunch.com/2026/05/27/tri… @dkhare @BaggaRohil

🚨 AI meets Oncology at @MountSinaiNYC The Tisch Cancer Center just rolled out PRISM, an AI-powered clinical trial matcher by Triomics, running on OncoLLM. 🧠 What it does: 🔹 Flags eligible trials earlier 🔹 Slashes manual chart review 🔹 Connects more NYC patients to cutting-edge research This isn’t just smart tech, it’s smarter access to cancer care. 📰 Full story via Pathology News: pathologynews.com/featured/mount… #Oncology #ClinicalTrials #CancerResearch #HealthTech #AI #PathologyNews #MountSinai

There's no bigger stage than Times Square, and this week at HITLAB that's exactly where Microsoft for Startups is putting the health and life sciences founders building what's next. This week featuring: 🧬 Triomics 💡 Cuezen ❤️ Octagos 🌊 Subsalt 🏥 Amenities Build fast, scale smart, sell more: msft.it/6049Qf9mU

.@MountSinaiNYC launches #AI #LLM platform for #clinicaltrials matching @Triomicsinc beckershospitalreview.com/healthcare-inf…

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗮𝗿𝗲 𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴, 𝗮𝗻𝗱 𝗔𝗜 𝗶𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗰𝗲𝗻𝘁𝗲𝗿 𝗼𝗳 𝘁𝗵𝗲 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻. Meet us June 18-19 at @HITHealthIMPACT, hosted at @Microsoft's NYC offices in Times Square, and discover how we're helping shape the future of healthcare. 𝗢𝗻 𝗧𝗵𝘂𝗿𝘀𝗱𝗮𝘆, 𝗝𝘂𝗻𝗲 𝟭𝟵 𝗮𝘁 𝟯:𝟭𝟱 𝗣𝗠 𝗘𝗗𝗧, @InSilicoTrials will take the stage at HealthIMPACT alongside Microsoft, as part of the Microsoft for Startups program. Our CEO, Luca Emili, will join Zach Taft, MBA, CEO at @IgniteData and Sebastien Rhodes, VP, Strategy and Operations at @Triomicsinc in the panel "𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗔𝗜 𝗶𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵", moderated by Colleen Healy, Senior Sales Director-U.S. Health & Life Sciences Microsoft, to share how AI is breaking down barriers in drug development, from trial design to patient recruitment. All panels will be moderated by @sallyafrank, Global Lead - Health & Life Sciences, and Colleen Healy. Don't miss this session on accelerating medical research with ethical, efficient, and intelligent solutions, and let’s connect during the event! More on the event: impactnyjune25.healthimpactlive.com/home #HealthImpact #AIinHealthcare #ClinicalTrials #DigitalHealth #MicrosoftforStartups #InSilicoTrials

Therica Miller @IcahnMountSinai is co-author on this paper in @npjDigitalMed: PRISM: Patient Records Interpretation for Semantic clinical trial Matching system using large language models rdcu.be/dY7sy

Matching patients to #ClinicalTrials is usually complex and time-consuming, often leaving patients unaware of potential treatment options. This study presents a custom fine-tuned language model that uses real-world patient data to automate trial matching, showing performance equal to qualified doctors and better than GPT-3.5 in identifying eligible patients. nature.com/articles/s4174…

Register now for the free webinar, Generative AI for Oncology Care and Research with @Triomicsinc . 📅 October 17 | 2:00 p.m. ET 📋 Register: lnkd.in/ekFD-SUV

Researchers at the @MedicalCollege & @CTSIWI are streamlining #ClinicalTrial matching for patients with #cancer using @Triomicsinc OncoLLM platform, which analyzes vast amounts of data in a fraction of the time it would take a human. Learn more: cancer.mcw.edu/stories/trailb…

Register now for the free webinar, Generative AI for Clinical Care and Research Use Cases with @Triomicsinc. 📅 October 17 | 2:00 p.m. ET 📋 Register: lnkd.in/ekFD-SUV

Hello from @valid_ai + Future & Health Summit, kicking off @jpmorgan '24. Thanks to @UCDavisHealth, @decimal_health, @domelabs, and @atreja for hosting. Our CEO, @k__sarim, spoke alongside @Google's @AashimaTweets , @SnowflakeDB's @JacinthLaval, and @UCSDHealth's @CALonghurst about #GenerativeAI use cases across care delivery and research. These include impact on access, workforce, and efficiency, as well as the need to standardize model validation and benchmarking.

Happy New Year. Here's to a happy and healthy 2024 as we look to #fightcancer with #genAI and our #LLM.

Thanks to @nodehealthorg, @UCDavisHealth, and Ashish Atreja, MD, MPH @atreja, for hosting the inaugural Valid AI summit yesterday in NYC. Our CEO @k__sarim was honored to share the stage with Microsoft's David Rhew, MD @drhew, @BestBuy's Diana Gelston, and moderator Kamal Jethwani @kamalj83 of @decimal_health. The panel spoke to three key points: (1) Aligning LLMs to the healthcare domain (2) Integrating Generative AI efficiently into existing processes (3) Top use cases for AI in Clinical Research Triomics is thrilled to be a Valid AI technology partner and looks forward to collaborating with the 40+ participating health systems to validate groundbreaking advances at the intersection of healthcare and technology. #clinicalresearch #GenerativeAI #LLMs

Just take a look at this agenda... its incredible! irp.cdn-website.com/14337b47/files… #NCI #CancerCenters #AMC #AI #DataScience #Omics #PrecisionMedicine #DiversityandInclusion #Triomics #CancerMoonshot #oncology #medeloop #AI #Informatics #CCSG @ASCO @PCFnews @SU2C @AACR @theNCI @NIH @GenomOncology @IASLC @IntegraConnect1 @TempusLabs @dnanexus @carisls @PwC @PwCUS @CDCgov @MoffittNews @WinshipAtEmory @dfcidatascience @DanaFarber @cityofhope @UPMC @OHSUKnight @OHSUInformatics @JCOCCI_ASCO @MDAndersonNews @DukeCancer @DukeHealth @TheCancerLetter @OSUCCC_James @CI4CC @NCIResearchCtr @NCIDirector @POTUS @Stanford @StanfordCancer @UCSDHealth @Reuters_Health @Reuters @VCUMassey @VCU @MountSinaiNYC

Join us in celebrating Ci4CC's milestone 10th anniversary! We're diving deep into the cutting-edge framework of Onco-LLM. Our expert panel will explore model intricacies, highlight Onco-LLM's pros and cons, and delve into its potential in clinical trials. #Ci4CC #OncoLLM